All
Trial Will Investigate Drug Duo in Solid Cancers With MAPK Pathway Aberrations
May 25th 2022Patients can still talk to their clinicians about enrolling in a sub-study of the FIRELIGHT-1 trial, analyzing tovorafenib plus pimasertib in progressive or refractory solid tumors with MAPK pathway aberrations.
Tuesday Persists Until All Patients With Cancer are Taken Care Of
May 20th 2022The care received by our patients (with cancer) has been described as “exemplary,” an incredible achievement for an infusion center that was a revolving door for short-term travel nurses with little-to-no full-time staff to provide the continuity of care that oncology nurses are well-known and admired for.